MRF-Logo2019-Horizontal-RGB
study of investigator with Dr. Rivas
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

study of investigator with Dr. Rivas

› Forums › General Melanoma Community › study of investigator with Dr. Rivas

  • Post
Viewing 2 reply threads
  • Replies
      • July 30, 2014 at 9:17 pm
      POW
      Participant

        I agree, the language in that report is difficult to understand. It might be easier for you to read the original research paper here:

        CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (see: http://clincancerres.aacrjournals.org/content/20/9/2424.full )

        The bottom line is that anti-CTL-4 antibodies (ipi; Yervoy) seem to increase the diverstiy of the T-cells in 80% of the patients. This may have a bearing on autoimmune side effects. It does not seem to be related to the effectiveness of the treatment. 

        • July 30, 2014 at 9:17 pm
        POW
        Participant

          I agree, the language in that report is difficult to understand. It might be easier for you to read the original research paper here:

          CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (see: http://clincancerres.aacrjournals.org/content/20/9/2424.full )

          The bottom line is that anti-CTL-4 antibodies (ipi; Yervoy) seem to increase the diverstiy of the T-cells in 80% of the patients. This may have a bearing on autoimmune side effects. It does not seem to be related to the effectiveness of the treatment. 

          • July 30, 2014 at 9:17 pm
          POW
          Participant

            I agree, the language in that report is difficult to understand. It might be easier for you to read the original research paper here:

            CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (see: http://clincancerres.aacrjournals.org/content/20/9/2424.full )

            The bottom line is that anti-CTL-4 antibodies (ipi; Yervoy) seem to increase the diverstiy of the T-cells in 80% of the patients. This may have a bearing on autoimmune side effects. It does not seem to be related to the effectiveness of the treatment. 

        Viewing 2 reply threads
        • You must be logged in to reply to this topic.
        About the MRF Patient Forum

        The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

        The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.